TREKIJECT Trademark

Trademark Overview

On Thursday, December 4, 2008, a trademark application was filed for TREKIJECT with the United States Patent and Trademark Office. The USPTO has given the TREKIJECT trademark a serial number of 77626317. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Tuesday, December 15, 2009. This trademark is owned by Novartis AG. The TREKIJECT trademark is filed in the Pharmaceutical Products category with the following description:

Injectors pre-filled with pharmaceutical preparations used to treat diseases and disorders of the central nervous system, immune system, cardiovascular system, respiratory system, musculoskeletal system and inflammatory disorders, and for use in dermatology and oncology
trekiject

General Information

Serial Number77626317
Word MarkTREKIJECT
Filing DateThursday, December 4, 2008
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateTuesday, December 15, 2009
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 7, 2009

Trademark Statements

Goods and ServicesInjectors pre-filled with pharmaceutical preparations used to treat diseases and disorders of the central nervous system, immune system, cardiovascular system, respiratory system, musculoskeletal system and inflammatory disorders, and for use in dermatology and oncology
Pseudo MarkTREK INJECTOR

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateTuesday, December 15, 2009
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNovartis AG
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBasel
CH
Party NameNovartis AG
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBasel
CH

Trademark Events

Event DateEvent Description
Tuesday, December 15, 2009ABANDONMENT NOTICE MAILED - AFTER PUBLICATION
Tuesday, December 15, 2009ABANDONMENT - AFTER PUBLICATION
Monday, December 14, 2009TEAS EXPRESS ABANDONMENT RECEIVED
Tuesday, October 27, 2009NOA MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, September 16, 2009TTAB RELEASE CASE TO TRADEMARKS
Wednesday, September 16, 2009OPPOSITION TERMINATED NO. 999999
Wednesday, September 16, 2009OPPOSITION DISMISSED NO. 999999
Thursday, August 6, 2009OPPOSITION INSTITUTED NO. 999999
Thursday, August 6, 2009EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, July 7, 2009PUBLISHED FOR OPPOSITION
Saturday, June 27, 2009TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, June 27, 2009TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, June 17, 2009NOTICE OF PUBLICATION
Thursday, June 4, 2009LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, June 4, 2009ASSIGNED TO LIE
Wednesday, June 3, 2009APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 3, 2009EXAMINER'S AMENDMENT ENTERED
Wednesday, June 3, 2009NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, June 3, 2009EXAMINERS AMENDMENT E-MAILED
Wednesday, June 3, 2009EXAMINERS AMENDMENT -WRITTEN
Tuesday, June 2, 2009TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, June 2, 2009CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 2, 2009TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, December 12, 2008NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, December 12, 2008NON-FINAL ACTION E-MAILED
Friday, December 12, 2008NON-FINAL ACTION WRITTEN
Thursday, December 11, 2008ASSIGNED TO EXAMINER
Tuesday, December 9, 2008NOTICE OF PSEUDO MARK MAILED
Monday, December 8, 2008NEW APPLICATION ENTERED IN TRAM

Related Keywords

trekiject system disorders immune cardiovascular respiratory musculoskeletal oncology dermatology inflammatory central